Satellos Bioscience Inc. (TSX: MSCL)
Health Care · Biotechnology · CA
CA$13.29
-1.63% today · +87.6% 1Y
Satellos Bioscience Inc. (TSX: MSCL) operates in the Biotechnology industry within the Health Care sector. The company is valued at $208.17M and employs 18 people.
Over the last twelve months the share price has gained 87.6%, trading between 6.96 and 18.98.
Tweenvest scores Satellos Bioscience Inc. across four factors: quality 26/100. Its strongest factor is quality.
MSCL price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $208.17M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.99
- Dividend yield
- —
- Beta (5Y)
- 1.17
- 52-week high
- CA$18.98
- 52-week low
- CA$6.96
- Avg volume (3M)
- —
- Shares outstanding
- 21.22M
- Employees
- 18
- Next earnings
- —
About Satellos Bioscience Inc.
Satellos Bioscience Inc., a biotechnology firm established in 2018 and headquartered in Toronto, Canada, specializes in developing regenerative therapies for degenerative muscle diseases. The company primarily operates in Canada and Australia, utilizing its proprietary MyoReGenX platform – an automated microscopy system engineered to replicate the muscle stem cell environment outside the body. A key focus for Satellos is the discovery and development of a small molecule drug specifically aimed at treating Duchenne muscular dystrophy.
- ISIN
- CA80401L8033
- Founded
- 2018
- Listed since
- Jan 7, 2008
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.